40+
Years of Experience
Continuous leadership in angioplasty and stent technology development.
CorSci LLC
Proven invention in cardiovascular intervention—now advancing the next era of vascular drug delivery.
Over four decades of angioplasty innovation, including active perfusion angioplasty and the nested loop stent, alongside current breakthrough work in drug-coated balloon delivery systems.
Innovation Legacy
40+ years
Trusted by strategic acquirers and innovation partners across cardiovascular intervention.
Credibility Metrics
Legacy of invention with measurable impact
Four decades of cardiovascular device innovation, translating breakthrough concepts into technologies adopted across the industry.
Actively advancing vascular drug delivery R&D
Dozens
Device Inventions
A broad patent legacy across angioplasty, perfusion, and stent platforms.
2
Landmark Firsts
Active perfusion angioplasty and the nested loop stent pioneered new care pathways.
Multiple
Acquisitions
Technologies acquired by leading global medical device companies.
Innovation strengths
Decades of cardiovascular invention, focused on today’s most critical delivery challenges
CorSci LLC combines inventor-level experience with a forward R&D agenda. Our portfolio is built on proven clinical impact and a disciplined approach to translational device development.
Innovation posture
Clinical-first engineering with strategic fit for large medtech platforms.
Angioplasty device invention
40+ years of developing angioplasty platforms that advanced procedural control, deliverability, and clinical adoption.
Active perfusion angioplasty
Pioneered perfusion-enabled systems to preserve flow during intervention, a milestone in high-risk coronary support.
Nested loop stent innovation
Engineered a structural stent concept that improved conformability and clinical outcomes, later adopted by industry leaders.
Strategic acquisition value
Multiple inventions acquired by major device companies, demonstrating scalable IP and integration-ready platforms.
Leadership in vascular drug delivery
Advancing a breakthrough device for controlled drug delivery from drug-coated balloons, aligning with next-generation therapy standards.
Current R&D focus
Innovation lineage
Four decades of cardiovascular device invention
CorSci LLC brings more than 40 years of cardiovascular engineering to today’s most urgent clinical challenges. From early angioplasty tools to the nested loop stent, the team has consistently delivered practical, patentable innovations that advanced patient care.
R&D environment
Design validation and lab testing for catheter-based platforms.
Device architecture
Precision components that enable controlled vascular drug delivery.
A record of breakthrough concepts
The company’s portfolio includes active perfusion angioplasty and multiple device platforms that moved from concept to clinical adoption. Each program reflects disciplined development, deep procedural insight, and an ability to solve complex vascular problems.
Proven pathways to acquisition
CorSci’s inventions have been acquired by major medical device companies—evidence of commercial readiness and strategic value. This experience informs today’s R&D: ideas are engineered with regulatory, manufacturing, and market integration in mind.
Focused on next‑generation drug delivery
Building on its legacy of invention, CorSci is advancing a novel device for vascular drug delivery from drug‑coated balloons, aiming to improve consistency, safety, and therapeutic outcomes.
40+ years of innovation
Angioplasty & stent invention
Acquisition-ready development
Current Development Focus
Advancing vascular drug delivery with a new device platform
CorSci LLC is developing a next‑generation device designed for vascular drug delivery from drug‑coated balloons. This program represents the next chapter in the company’s innovation pipeline—applying decades of interventional expertise to improve how therapeutic agents are delivered during angioplasty.
The focus is on delivery precision and procedural integration, supporting clinicians with a thoughtfully engineered system that aligns with contemporary interventional practice. We engage with partners and strategic acquirers to ensure the platform advances clinical utility and aligns with real‑world workflow needs.
R&D Program
- Therapeutic delivery precision
- Engineered to improve how drug‑coated balloon therapies are delivered within the vessel environment.
- Interventional workflow alignment
- Designed with procedural efficiency in mind, complementing established angioplasty techniques.
- Partnership‑ready development
- Structured for collaboration with strategic partners and acquirers seeking differentiated vascular therapy solutions.
This development effort builds directly on CorSci’s legacy of invention in angioplasty and stent technologies.
Industry trust
Acquired by leading medical device companies
CorSci inventions have been acquired and integrated into the portfolios of large cardiovascular device companies, underscoring the clinical relevance and commercial durability of our innovations.
Technology validated by strategic acquirers
Proven pathways to market adoption
Acquisition readiness
OngoingOur platform innovations are engineered for integration within established cardiovascular portfolios.
IP lineage
40+ yearsA multi-decade record of inventions that progress from clinical concept to industry-standard devices.
Strategic alignment
PartneredFocused on collaborations that accelerate market access and clinical impact.
Principals
Leadership grounded in decades of cardiovascular invention
CorSci LLC is led by seasoned inventors and clinical innovators with a long track record of advancing angioplasty and stent technology, now focused on next-generation vascular drug delivery.
Leadership focus
A compact, principle-driven team delivering rigorous engineering, disciplined clinical insight, and a history of successful technology transfer.
Principal
Leadership Profile
Experienced cardiovascular device inventor overseeing translational strategy and clinical adoption pathways.
Principal
Innovation Lead
Drives advanced engineering development and intellectual property strategy across core platforms.
Principal
Clinical Strategy
Guides clinical validation, regulatory readiness, and partnership alignment for translational impact.
FAQ
Clarity for strategic partners
Concise answers about CorSci LLC’s expertise, legacy of invention, and current vascular drug delivery development.